title: [Evaluation of the efficacy of antiparasitic drugs in the treatment of concurrent parasitic diseases in patients with HIV infection and in those with pulmonary tuberculosis].
abstract: The efficacy of albendazole (400 mg taken once), mebendazole (100 mg taken once), and metronidazole (0.5 g thrice daily for 7 days) was evaluated when treating ascariasis, enterobiosis, and blastocystosis, respectively, in patients with HIV infection and in those with pulmonary tuberculosis. Metronidazole-resistant lambliasis was treated with exdisten (5 mg four times for 10 days) in 30.4% of the patients with HIV infection and in 43.3% of those with tuberculosis. Most HIV infected patients received antiretroviral therapy (ARVT). All the tuberculosis patients took isoniazid, ethambutol, pyrazinamide, rifampicin, and streptomycin. Efficiency was monitored by triple coproscopy at an interval of 5-7 days and by additional examinations using the method of Ritchii et al. There was parasitological cure (decreased infection rate for blastocystosis) and clinical improvement as positive changes in symptoms, such as nausea, weakness, headache, weight loss, and others, in all the patients with concomitant ascariasis, enterobiosis, and lambliasis. ARVT and antituberculosis drugs were observed to be better tolerated in all cases.
authors.forename: N A
authors.initials: NA
authors.lastname: Davis
authors.forename: Kh Z
authors.initials: KhZ
authors.lastname: Giiasov
authors.forename: Zh I
authors.initials: ZhI
authors.lastname: Islamova
authors.forename: L N
authors.initials: LN
authors.lastname: Tuĭchiev
authors.forename: N N
authors.initials: NN
authors.lastname: Parpieva
authors.forename: V G
authors.initials: VG
authors.lastname: Belotserkovets
authors.forename: Z B
authors.initials: ZB
authors.lastname: Dzhuraeva
authors.forename: V N
authors.initials: VN
authors.lastname: Syrov
authors.forename: D B
authors.initials: DB
authors.lastname: Faĭzullaeva
authors.forename: E S
authors.initials: ES
authors.lastname: Papina
authors.forename: B N
authors.initials: BN
authors.lastname: Baimbetov
authors.forename: S O
authors.initials: SO
authors.lastname: Osipova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015766:Albendazole / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001196:Ascariasis / Q000150:complications / Q000188:drug therapy / Q000469:parasitology; D016776:Blastocystis Infections / Q000150:complications / Q000188:drug therapy / Q000469:parasitology; D017229:Enterobiasis / Q000150:complications / Q000188:drug therapy / Q000469:parasitology; D005243:Feces / Q000469:parasitology; D005260:Female; D005873:Giardiasis / Q000150:complications / Q000188:drug therapy / Q000469:parasitology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology
chemical_list: D019380:Anti-HIV Agents; D000977:Antiparasitic Agents; D000995:Antitubercular Agents; D008795:Metronidazole; D008463:Mebendazole; D015766:Albendazole